The human clinical trial for tawa-tawa as an adjunctive COVID-19 treatment was just starting.
The human clinical trial on the use of tawa-tawa or Euphorbia hirta as an adjunctive COVID-19 treatment was just starting.
In a report on Manila Bulletin, the clinical trial on the use of tawa-tawa as an adjunctive treatment of mild to moderate COVID-positive patients was just starting.
This was relayed by Dr. Philip Ian Padilla of the University of the Philippines Visayas (UP Visayas) to Department of Science and Technology (DOST) Secretary Fortunato “Boy” de la Peña last Friday.
When asked about the status of the tawa-tawa clinical trial after de la Peña’s weekly report, Padilla informed de la Peña that unlike in lagundi clinical trials that they’re almost finished the tawa-tawa clinical trial was just starting.
Padilla also said that they can hopefully recruit the initial batch of COVID-positive patients in Bacolod City by April because there were many patients in the city who caught mild and moderate COVID-19 in Western Visayas.
READ ALSO: Human Clinical Trials For Lagundi As COVID-19 Supplement Near Completion
“Unlike sa lagundi [trials] na halos matatapos na sila, ang tawa-tawa clinical trial nagsisimula pa lang. Hopefully, by April, nakarecruit tayo ng initial batch of patients lalo na sa Bacolod kasi mas marami na pasyente na nagkaroon ng mild at moderate [COVID] dito sa Western Visayas,” Padilla said.
Padilla also said that the clinical trial for tawa-tawa had been slightly delayed “because of bureaucratic red tape”, adding that the recruitment of the COVID-positive patients was starting and so it will take another 4-6 months in order to get all the needed data.
Tawa-tawa was known as a supplement for dengue.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.
